US FDA’s 2025 Staffing Turmoil Will Create 2026 Application Review Challenges

 
• By Sue Sutter
  
Car mirror
The FDA's drug review performance in 2026 will reflect the turmoil of 2025. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA

More from United States